Xenazine in Late Dyskinetic Syndrome With Neuroleptics

PHASE3CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

May 14, 2012

Primary Completion Date

May 18, 2017

Study Completion Date

August 31, 2017

Conditions
Tardive Dyskinesia
Interventions
DRUG

Tetrabenazine

"Treatment with tetrabenazine consists in:~* 5-week titration to a maximum dose of 200 mg / day~* 5 weeks at stable dose~* 2 weeks in wash-out~The treatment will be blinded for patients and investigators"

DRUG

Placebo

"Treatment with placebo consists in:~* 5-week titration to a maximum dose of 200 mg / day~* 5 weeks at stable dose~* 2 weeks in wash-out~The treatment will be blinded for patients and investigators"

Trial Locations (19)

13100

CH Aix en Provence, Aix-en-Provence

13385

AP-HM Hopital de la Timone, Marseille

14033

CHU Caen, Caen

30900

CHRU de Nimes, Nîmes

31059

CHU Toulouse, Toulouse

33076

CHU Bordeaux, Bordeaux

34295

CHU Montpellier, Montpellier

35033

CHU de Rennes, Rennes

44093

CHU Nantes, Nantes

59037

CHRU Lille, Lille

63003

CHU Clermont-Ferrand, Clermont-Ferrand

67091

CHU Strasbourg, Strasbourg

69100

CH des Charpennes, Lyon

75012

CHU Saint Antoine, Paris

76031

CHU Rouen, Rouen

80000

CHU Amiens, Amiens

86021

CHU Poitiers, Poitiers

87042

CHU Limoges, Limoges

06002

CHU Nice, Nice

All Listed Sponsors
lead

Centre Hospitalier Universitaire, Amiens

OTHER

NCT01543321 - Xenazine in Late Dyskinetic Syndrome With Neuroleptics | Biotech Hunter | Biotech Hunter